AzTrials
AzTrials

Necrotizing EnterocolitisNOR-NECNCT06757582

Necrotizing Enterocolitis and Bowel Perforation in Very Preterm Infants - Long-term Follow up

An observational study of Necrotizing Enterocolitis and Intestinal Perforation, run by University Hospital of North Norway at 1 site in Norway.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record
Search all trials

Trial summary

Necrotizing enterocolitis (NEC) is a gastrointestinal syndrome characterized by transmural inflammation and necrosis of the large and/or small bowel and subsequent intramural gas-forming organisms into the intestinal wall. Read more about this study

Who is it for?
Ages 6 to 15 years
How many people
150 participants
Where
1 siteNorway
Study dates
1 Feb 2025to 1 Aug 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 6 to 15 years
  • All sexes
  • No healthy volunteers
  • Child

Study population: Cases and Controls will be identified through the Norwegian Neonatal Network.

Who may be able to join

  • Case: All Norwegian very preterm infants (gestational age (GA) < 32 weeks) born during the 6-year period 2008-2013, diagnosed with surgical NEC or bowel perforation and surviving up to one year of age will be invited to participate as cases.
  • Controls: For each case we will invite two controls matched for important clinical characteristics (e.g. sex, GA, clinical illness score, intracranial pathology, need for oxygen at discharge etc.).

Who cannot join

  • not signing informed consent scheme

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Claus Klingenberg, MD, PhD contact

91563167 ext. +47

claus.klingenberg@unn.no

Norway1 site
  • University Hospital of North Norway

    Tromsø, N-9038

Other trials in Norway

About this study

Necrotizing enterocolitis (NEC) is a gastrointestinal syndrome characterized by transmural inflammation and necrosis of the large and/or small bowel and subsequent intramural gas-forming organisms into the intestinal wall. Some preterm infants also develop spontaneous intestinal perforations (SIP) without the classical bowel inflammation/necrosis seen in NEC. NEC and SIP can be challenging to differentiate. Severe cases of both conditions require surgery and often bowel resection, but mortality due to SIP seems lower.

Studies looking at "long-term prognosis" of infants with NEC and bowel perforation have mainly assessed outcome until 2-7 years of age. The primary school years is a vulnerable period for ex-preterm children. Disruption in learning and social integration is of great importance for their quality of life (QoL), but little data exist in this age group. Moreover, nutritional deficits (e.g. cobalamin- or iron-deficiency may impact cognitive development, but this has not been investigated in this "high-risk" population in school age. Authors of a recent systematic review on gastrointestinal sequel after NEC-surgery thus called for "more high-quality studies assessing long-term follow-up".

In this project we will study the long-term impact of surgery for NEC and bowel perforation in preterm infants, both with a quality of life (QoL) perspective and with a focus on development, growth, nutrition and persistent gastrointestinal problems.

Read the detailed description

INTRODUCTION

Necrotizing enterocolitis (NEC) is a gastrointestinal syndrome characterized by transmural inflammation and necrosis of the large and/or small bowel and subsequent intramural gas-forming organisms into the intestinal wall. The incidence of NEC is inversely related to birth weight and gestational age (GA), with the majority of affected being very preterm infants (GA < 32 weeks), and in particular extremely preterm infants (GA < 28 weeks). In Scandinavia, the rates of NEC in extremely preterm infants is 6-9% (1-3). NEC is a devastating condition and one of the four main causes of mortality in neonatal intensive care units (NICUs) (4). Some preterm infants also develop spontaneous intestinal perforations (SIP) without the classical bowel inflammation/necrosis seen in NEC. NEC and SIP can be challenging to differentiate. Severe cases of both conditions require surgery and often bowel resection, but mortality due to SIP seems lower (5).

The clinical onset of NEC is usually in the second or third week of life. Typical symptoms and signs are a distended abdomen, periumbilical erythema, bloody stools, feeding intolerance and a generally unstable infant. However, the signs are non-specific, and the diagnosis is usually based on radiographic findings such as intramural bowel gas (6, 17, 18). The severity is classified by modified Bells criteria (18, 19). Stage I refers to suspected, but unconfirmed NEC. Stage II is radiographically confirmed NEC requiring medical therapy including broad-spectrum antibiotics and supportive care. Stage III patients demonstrate clinical signs of bowel necrosis, peritonitis, and septic shock, or radiographic findings of bowel perforation. These patients often receive surgery in addition to intensive care. The mortality rate of NEC is between 20-40%; highest in immature infants and/or stage III disease (20, 21).

Survivors of severe NEC (stage III) require long and often very intensive medical therapy that cause suffering for both patients and their families (18, 20). Moreover, medical therapy of patients with NEC requires huge resources for the neonatal unit and the health care system (20). Those who survive NEC have an increased risk of later gut-associated problems (e.g. short bowel syndrome and strictures) (18, 22), and neurodevelopmental disability (20, 23). Similar results have been observed in follow-up studies after SIP, but less data is available for this condition (23).

Although significant progress has been made in our understanding of NEC/SIP over the last decade, many questions remain regarding the long-term prognosis and optimal follow-up.

Studies looking at "long-term prognosis" of infants with NEC and bowel perforation have mainly assessed outcome until 2-7 years of age (20, 24). The primary school years is a vulnerable period for ex-preterm children. Disruption in learning and social integration is of great importance for their quality of life (QoL), but little data exist in this age group (25). Moreover, nutritional deficits (e.g. cobalamin- or iron-deficiency (26, 27) may impact cognitive development, but this has not been investigated in this "high-risk" population in school age. Authors of a recent systematic review on gastrointestinal sequel after NEC-surgery thus called for "more high-quality studies assessing long-term follow-up" (28).

In this project we will study the long-term impact of surgery for NEC and bowel perforation in preterm infants, both with a quality of life (QoL) perspective and with a focus on development, growth, nutrition and persistent gastrointestinal problems.

AIM

to collect long-term follow-up data on QoL, growth, development, biochemical nutritional status and persistent gastrointestinal symptoms among survivors of surgical NEC or bowel perforation in the neonatal period, in order to identify areas where we can improve or optimize follow-up.

RESEARCH QUESTION

What is the long-term outcome of preterm infants surviving surgical NEC or bowel perforation in the neonatal period?

Keywords
necrotizing enterocolitis, bowel perforation, preterm infant, long-term follow-up, quality of life
Medical subject headings
Enterocolitis, Necrotizing, Intestinal Perforation, Premature Birth

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Pediatric quality of life (PedsQL) questionnaire

    modular approach measuring health-related QoL in children and adolescents (2-18 years) incl. children with acute and chronic health conditions. This questionnaire comprises of 4 essential core domains namely: Physical Functioning, Emotional Functioning, Social Functioning and School Functioning.

    Measured: 2020-2021

Secondary outcomes (6)
  1. Pediatric quality of life (QoL) Gastrointestinal Symptoms

    Validated questionnaire assessing gastrointestinal problems.The questionnaire reports data on gastrointestinal symptoms, within 10 scales. The final score goes from 0-100 and higher values indicates less symptoms and better QoL.

    Measured: 2025

  2. 5-15-R

    a standardized questionnaire for parents covering development and behavior of children and adolescents in ages 5 to 17 years

    Measured: 2025

  3. Blood samples

    Hb, leukocytes with differential count, platelets, reticulocytes, mean corpuscular volume, Hb in reticulocytes, ferritin, 25-OH vitamin D, cobalamine, urea, creatinine, calcium, phosphorous, 9 essential trace elements, a broad panel of other fat and water soluble vitamins.

    Data will be reported in SI units, or other conventional measures.

    For this outcome we will report data on number of participants with 1, 2, 3 or 4 or more abnormal laboratory values

    Measured: 2025

  4. Weight

    in kilogram and one decimal (e.g. 24.8 kg)

    Measured: 2025

  5. Height

    in cm

    Measured: 2025

  6. Head circumference

    in cm and one decimal (e.g. 45.7 cm)

    Measured: 2025

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Jan 2025
  2. Study start1 Feb 2025 (estimated)
  3. Primary completion1 Aug 2026 (estimated)
  4. Study completion1 Aug 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Cross-sectional
Enrolment
150 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06757582
Sponsor's protocol ID
2018/1976/REK nord
Acronym
NOR-NEC
Status last verified
Jan 2025
First submitted
2 Jan 2020
Last updated
3 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No: no plan to share IPD for this study which is not a RCT

Publications

  • Hau EM, Meyer SC, Berger S, Goutaki M, Kordasz M, Kessler U. Gastrointestinal sequelae after surgery for necrotising enterocolitis: a systematic review and meta-analysis. Arch Dis Child Fetal Neonatal Ed. 2019 May;104(3):F265-F273. doi: 10.1136/archdischild-2017-314435. Epub 2018 Jun 26.

    PubMed 29945925
  • Neu J. Necrotizing enterocolitis: the mystery goes on. Neonatology. 2014;106(4):289-95. doi: 10.1159/000365130. Epub 2014 Aug 20.

    PubMed 25171544

Questions about this trial

What is this clinical trial studying?

An observational study of Necrotizing Enterocolitis and Intestinal Perforation, run by University Hospital of North Norway at 1 site in Norway.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: opening soon, as of the sponsor's last update on 3 Jan 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Claus Klingenberg, MD, PhD (91563167 ext. +47, claus.klingenberg@unn.no), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Pediatric quality of life (PedsQL) questionnaire (time frame: 2020-2021). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT06757582, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Jan 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in